Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Argus Health
Merck
Dow
Fuji
Healthtrust
Cerilliant
Mallinckrodt
Medtronic

Generated: December 19, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CINACALCET HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Cinacalcet Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00094484 Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis Completed Amgen Phase 3 The purpose of this study is to evaluate the efficacy and safety of cinacalcet compared with placebo in patients with stage 3 and 4 Chronic Kidney Disease (CKD).
NCT00110890 A Research Study for Patients With End-Stage Renal Disease (ESRD) Completed Amgen Phase 4 The purpose of this study is to evaluate the ability of a treatment strategy, that includes cinacalcet for the management of secondary hyperparathyroidism, to control parathyroid hormone (PTH) compared with the standard of care.
NCT00113945 Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD) Completed Amgen Phase 2 The purpose of this study is to observe the effects of a treatment strategy that incorporates cinacalcet HCl into the management of secondary hyperparathyroidism (HPT) in subjects with ESRD receiving hemodialysis, on bio-intact parathyroid hormone (biPTH), corrected serum calcium, serum phosphorus, and calcium phosphorus product.
NCT00113958 Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels Completed Amgen Phase 2 The purpose of this study is to observe the effects of a treatment strategy that incorporates cinacalcet HCl into the management of secondary hyperparathyroidism (HPT) to K/DOQI recommended targets in subjects with end stage renal disease (ESRD) receiving hemodialysis, on bio-intact parathyroid hormone, corrected serum calcium, serum phosphorus, and calcium phosphorus product.
NCT00117052 SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism Completed Amgen Phase 3 The purpose of this study is to demonstrate that the efficacy of cinacalcet when co-administered with the first meal after dialysis is comparable (non-inferior) to the efficacy of cinacalcet when administered during the dialysis study visit.
NCT00195936 Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets Unknown status Children's Mercy Hospital Kansas City Phase 1 This study will measure the effect of cinacalcet (Sensipar) on parathyroid hormone (PTH) secretion in children and adolescents with hypophosphatemic rickets (XLH). The investigators are seeking evidence that patients with XLH may benefit from treatment with cinacalcet by achieving better control of PTH secretion.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Cinacalcet Hydrochloride

Condition Name

Condition Name for Cinacalcet Hydrochloride
Intervention Trials
Secondary Hyperparathyroidism 22
Chronic Kidney Disease 13
Hyperparathyroidism, Secondary 6
End Stage Renal Disease 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Cinacalcet Hydrochloride
Intervention Trials
Hyperparathyroidism 41
Hyperparathyroidism, Secondary 31
Neoplasm Metastasis 25
Kidney Diseases 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Cinacalcet Hydrochloride

Trials by Country

Trials by Country for Cinacalcet Hydrochloride
Location Trials
United States 158
Spain 22
France 17
Canada 11
Italy 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Cinacalcet Hydrochloride
Location Trials
New York 12
California 11
Missouri 10
Texas 9
Pennsylvania 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Cinacalcet Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Cinacalcet Hydrochloride
Clinical Trial Phase Trials
Phase 4 17
Phase 3 13
Phase 2/Phase 3 3
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Cinacalcet Hydrochloride
Clinical Trial Phase Trials
Completed 33
Terminated 6
Recruiting 6
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Cinacalcet Hydrochloride

Sponsor Name

Sponsor Name for Cinacalcet Hydrochloride
Sponsor Trials
Amgen 26
Children's Mercy Hospital Kansas City 2
Montefiore Medical Center 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Cinacalcet Hydrochloride
Sponsor Trials
Other 34
Industry 31
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Daiichi Sankyo
Federal Trade Commission
Farmers Insurance
McKesson
Cantor Fitzgerald
Colorcon
US Army
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.